Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

Astrotech Corporation. (11/14/14). "Press Release: Astrotech Reports First Quarter 2015 Financial Results". Austin, TX.

Organisations Organisation Astrotech Corporation (Nasdaq: SPAB)
  Today University of Virginia, School of Medicine
  Group Astrotech (Group)
  Organisation 2 1st Detect Corporation
  Group Astrotech (Group)
Product Product iONTRAC process monitor
Persons Person Pickens, Thomas B. (Astrotech 201201 CEO of Astrotech + Chairman 1st Detect Corp)
  Person 2 Stober, Eric (Astrotech 201411 CFO)
     


Quarterly Highlights

> GAAP results: net income of $23.3 million (attributable to Astrotech Corporation), or $1.16 per diluted share for the quarter ended September 30, 2014

> The sale of Astrotech Space Operations (“ASO”) to Lockheed Martin was completed on August 22, 2014 for an agreed upon purchase price of $61.0 million, less a working capital adjustment of $1.7 million

> Adjusted EBITDA of $23.1 million from continuing operations for the quarter ended September 30, 2014, which includes a gain from the sale of our former ASO business

> 1st Detect was awarded a pivotal competitive contract for the Next Generation Chemical Detector (NGCD) program

> 1st Detect was granted one U.S. patent and two International patents during the quarter


Astrotech Corporation (NASDAQ: ASTC), a premier developer of innovative chemical detection technologies for use in the research, security, industrial, process flow and healthcare markets, today announced financial results for its first quarter ended September 30, 2014.

“I want to begin by saying that the sale of Astrotech Space Operations to Lockheed Martin went extremely well, and I would like to commend both the Astrotech and Lockheed M&A teams for concluding an absolutely flawless transaction. The executive staff at Astrotech internally sourced the transaction and managed all of our own negotiations, the structure of the asset sale, tax considerations, contracts and the post sale transition resulting in receiving an excellent price for our shareholders. With the conclusion of this transaction we begin a new era to grow the company with well seasoned leadership and ample resources. At the base of our growth is the Company’s investment in our 1st Detect subsidiary where we have made excellent progress with our mass spectrometer technology. Our recently announced award from the military’s Next Generation Chemical Detector program represents a big win as our technology was chosen over the best the world has to offer. We have also recently introduced the iONTRAC factory floor in-process monitor at the Gulf Coast Conference, winning bronze in their New Product Showcase. The iONTRAC is designed to pursue the many opportunities controlling processes and quality throughout numerous factory floor industrial applications," said Thomas B. Pickens III, Chairman and CEO of Astrotech Corporation. “Additionally, we are actively seeking acquisitions along with complementary and new technology commercialization opportunities.”


First Quarter Results

The Company posted first quarter fiscal year 2015 net income of $23.3 million, or $1.16 per diluted share, which was primarily the result of a $25.6 million gain ($23.7 million after-tax) related to the sale of our former ASO business to Lockheed Martin, compared with a first quarter fiscal year 2014 net income of $1.3 million or $0.06 per diluted share.

Financial Tables for First Quarter and Fiscal Year 2015 [PDF 38KB] [ http://astrotechcorp.com/files/atec/documents/FY2015_Press_Release_10Q_Q1_FINALtables.pdf ]


Financial Position and Liquidity

Working capital was $44.1 million as of September 30, 2014, which primarily consisted of $45.3 million in cash and cash equivalents, and a working capital holdback receivable of $0.6 million related to the sale of our former ASO business. Additionally, the Company recorded a receivable of $6.1 million for an indemnity holdback related to the sale. The Company believes it will fully realize the indemnity holdback in February 2016.


About Astrotech Corporation

Astrotech is a leader in identifying and commercializing space technology for terrestrial use. 1st Detect Corporation is developing a breakthrough miniaturized mass spectrometer, the MMS-1000™, while Astrogenetix, Inc. is a biotechnology company utilizing microgravity as a research platform for drug discovery and development. Both are wholly owned subsidiaries of the parent.


This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, our ability to successfully develop our remaining Spacetech business unit, our ability to develop and integrate our miniaturized mass spectrometer, the MMS-1000™, product performance and market acceptance of products and services, as well as other risk factors and business considerations. Any forward-looking statements in this document should be evaluated in light of these important risk factors. Astrotech assumes no obligation to update these forward-looking statements.

FOR MORE INFORMATION:
Eric Stober
Chief Financial Officer
Astrotech Corporation
512.485.9530

   
Record changed: 2016-03-19

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for Astrotech (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px